This week's Philadelphia-area life sciences industry update includes a women's oncology company identifying a lead product candidate, a biopharmaceutical company's multimillion-dollar licensing deal, a biotech firm initiating human clinical trials, and more.
Here's the roundup:
The Philadelphia-based women's oncology company selected CTIM-76 as its lead clinical development candidate targeting Claudin 6 (CLDN6) positive cancers.
CLDN6-enriched cancers include ovarian, endometrial, testicular,…
